Cengiz Bayram

Ankara Children's Hematology Oncology Training and Research Hospital, Engüri, Ankara, Turkey

Are you Cengiz Bayram?

Claim your profile

Publications (12)10.54 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Improvement in long-term survival in patients with acute childhood leukemia has led to the need for monitorization of chemotherapy-related morbidity and mortality. This study included 60 patients with acute lymphoblastic leukemia that were in remission for at least 2 years and 30 healthy controls. Systolic and diastolic function of myocardium was evaluated using conventional echocardiography and tissue Doppler imaging of the left ventricle, interventricular septum and right ventricle. Median age of patients was 11.7 years (range 10–14.9 years), and the median duration of remission was 4 years (range 2.5–5 years). All patients were treated with a low cumulative dose of adriamycin (100 mg/m2) according to the St. Jude Total-XIIIA protocol. The ejection fraction (EF) and fractional shortening were normal in the patient and control groups, even though EF values were significantly lower in the patients (69.5 ± 2.3 vs. 72.7 ± 3 %, P < 0.01). Myocardial systole (S m), early diastole (E m) and late diastole (A m) velocities in all segments of the myocardium were significantly lower in the patient group (P < 0.01 for all segments). Cardiotoxicity was noted in all segments of the myocardium in the patient group, despite the fact that they were all treated with a low cumulative dose of adriamycin. Based on these findings, we think that there is no safe dose for anthracyclines and periodic echocardiographic evaluation of both the left and right ventricles must be performed in all patients treated with anthracyclines, even at low doses.
    Pediatric Cardiology 01/2015; 36(4). DOI:10.1007/s00246-015-1096-6 · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections (IFIs) constitute a leading cause of morbidity and infection-related mortality among hematopoietic stem cell transplant (HSCT) recipients. With the use of secondary prophylaxis, a history of IFI is not an absolute contraindication to allo-HSCT. However, still, IFI recurrence remains a risk factor for transplant-related mortality. In this study, of the 105 children undergoing HSCT between April 2010 and February 2013, 10 patients who had IFI history before transplantation and had undergone allo-HSCT were evaluated retrospectively to investigate results of secondary prophylaxis. In conclusion, our study shows that amphotericin B and caspofungin was successful as secondary antifungal prophylaxis agents with no relapse of IFI. In addition, after engraftment, secondary prophylaxis was continued with voriconazole orally in 4 patients that yielded good results.
    Journal of Pediatric Hematology/Oncology 01/2015; 37(1):e19-e22. DOI:10.1097/MPH.0000000000000175 · 0.96 Impact Factor
  • Source
    Bayram C · Çetin İ · Tavil B · Yarali N · Ekici F · Isık P · Tunc B.
    [Show abstract] [Hide abstract]
    ABSTRACT: Improvement in long-term survival in patients with acute childhood leukemia has led to the need for monitorization of chemotherapy-related morbidity and mortality. This study included 60 patients with acute lymphoblastic leukemia that were in remission for at least 2 years and 30 healthy controls. Systolic and diastolic function of myocardium was evaluated using conventional echocardiography and tissue Doppler imaging of the left ventricle, interventricular septum and right ventricle. Median age of patients was 11.7 years (range 10-14.9 years), and the median duration of remission was 4 years (range 2.5-5 years). All patients were treated with a low cumulative dose of adriamycin (100 mg/m2) according to the St. Jude Total-XIIIA protocol. The ejection fraction (EF) and fractional shortening were normal in the patient and control groups, even though EF values were significantly lower in the patients (69.5 ± 2.3 vs. 72.7 ± 3 %, P < 0.01). Myocardial systole (S m), early diastole (E m) and late diastole (A m) velocities in all segments of the myocardium were significantly lower in the patient group (P < 0.01 for all segments). Cardiotoxicity was noted in all segments of the myocardium in the patient group, despite the fact that they were all treated with a low cumulative dose of adriamycin. Based on these findings, we think that there is no safe dose for anthracyclines and periodic echocardiographic evaluation of both the left and right ventricles must be performed in all patients treated with anthracyclines, even at low doses.
    Pediatric Cardiology 01/2015; · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Hb Adana (HBA1: c.179G > A) is a very rare, unstable form of α-globin variant that results from deficient synthesis of functional α chains. We present a 2-month-old boy with hypochromic microcytic anemia, and remarkable anisocytosis, target cells and basophilic stippling on his peripheral blood smear. α-Globin gene analysis of the patient determined homozygosity for HBA1: c.179G > A, a mutation known as Hb Adana. On his follow-up visit, hemoglobin (Hb) levels were stable at 9.0-9.5 g/dL and mean corpuscular volume (MCV) was 62.2-62.5 fL without the need for a blood transfusion. Clinical and hematological findings of our case were comparable to Hb H (β4) or β-thalassemia intermedia (β-TI)-like phenotypes, despite the fact that he carried an α1 gene mutation. Heterozygosity for the HBA1: c.179G > A mutation may also lead to microcytosis only as seen in his parents. According to our current knowledge, this is the first described case with homozygosity for the Hb Adana mutation, carried on the α1 gene. The relatively mild presentation of the case highlights the milder phenotypic consequences of nondeletional α mutations in the α1 vs. the α2 gene.
    Hemoglobin 10/2014; 38(6):1-2. DOI:10.3109/03630269.2014.969373 · 0.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we retrospectively examined the data of children who underwent allo-HSCT from HLA-matched family donors. We analyzed the incidence, etiological factors, clinical characteristics, possible reasons, risk factors, and follow-up of neurologic complications. BU-based conditioning regimens were used in most of the cases (n = 62). The median duration of follow-up for the 89 patients was 20 months (range 1–41 months). Eleven percent of transplanted children developed one or more neurological symptoms after HSCT with a median observation time of two months (range −6 days to 18 months). The median age of the four girls and six boys with neurological complication was 13 yr (range 5.3–17.6 yr). Cylosporine A neurotoxicity was diagnosed in five children, four of them were PRES. The rest of complications were BU and lorazepam toxicity, an intracranial hemorrhage, a sinovenous thrombosis, and a transient ischemic attack during extracorpereal photopheresis. No difference was found between groups of neurological complication according to age, gender, diagnosis, hospitalization time, neutrophil and platelet engraftment time, stem cell source, and conditioning regimen, acute and chronic GVHD or VOD. Neurological complication was the cause of death in one patient (1.1%).
    Pediatric Transplantation 06/2014; 18(4). DOI:10.1111/petr.12265 · 1.63 Impact Factor
  • Source
    Zekai Avcı · Cengiz Bayram · Barış Malbora
    Turkish Journal of Haematology 12/2013; 30(4):418-9. DOI:10.4274/Tjh-2013.0226 · 0.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The beta thalassemias are common genetic disorders in Turkey and in this retrospective study our aim was to evaluate β-globin chain mutations and the phenotypic severity of β-thalassemia patients followed-up in our hospital, a tertiary center which serves patients from all regions of Turkey. 106 pediatric patients were analysed for β-globin gene mutations by using DNA analysis. Patients were classified as having β-thalassemia major or β-thalassemia intermedia based on age at diagnosis, transfusion frequency and lowest hemoglobin concentration in between transfusions. There were 106 patients (52.8% female and 47.2% male) with a mean age of 11.2±5 years (1.6 - 22.3 years). Eighty-four (79.2%) patients had β-thalassemia major, whereas the remaining 22 patients (20.8%) were identified as having β-thalassemia intermedia. Overall, 18 different mutations were detected on 212 alleles. The most frequently encountered mutation was IVS I.110 (G>A) (35.3%), followed by Codon 8 del-AA (10.4%), IVS II.1 (G>A) (8%), IVS I.1 (G>A) (7.5%), Codon 39 (C>T) (7.1%) and Codon 5 (-CT) (6.6%), which made up 79.4% of observed mutations. According to present results, IVS I.110 (G>AA) was the most frequent mutation observed in this study, as in other results from Turkey. Evaluation of β-thalassemia mutations in 106 patients with 212 alleles, revealed the presence of homozygous mutation in 85 patients (80.2%) and compound heterozygous mutation in 21 patients (19.8%). The mutations detected in patients with homozygous mutation were IVS I.110 (G>A) (38.8%), Codon 8 del -AA (11.8%), IVS II.1 (G>A) (8.2%) and IVS I.1 (G>A) (8.2%). Observed mutations in the compound heterozygotes were Codon 39 (C>T)/Codon 41-42 (-CTTT) (14.3%), IVS I.110 (G>A)/Codon 39(C>T) (14.3%), IVS I.110 (G>A)/Codon 44(-C) (14.3%), and IVS II.745 (C>G)/5'UTR + 22 (G>A) (9.5%). Our hospital is a tertiary referral center that provides care to patients from all over the country, and thus the distribution of mutations observed in the current study is significant in term of representing that of the country as a whole.
    Mediterranean Journal of Hematology and Infectious Diseases 09/2013; 5(1):e2013055. DOI:10.4084/MJHID.2013.055
  • Journal of Pediatric Hematology/Oncology 05/2013; 36(8). DOI:10.1097/MPH.0b013e318290bf31 · 0.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chordoma is a locally aggressive but a slow-growing and rare malignant tumor. It arises from ectopic rests of notochordal tissue and it is most commonly seen in the sacral region (50% to 60%), skull base (35%), and spinal column (15%). At imaging, a chordoma typically manifests as a large destructive sacral mass with secondary soft-tissue extension. Differential diagnosis includes giant cell tumor, chondrosarcoma, metastasis, myxopapillary ependymoma, and plasmacytoma. The optimal treatment for sacral chordoma is en bloc sacral resection with wide surgical margins. The purpose of this study is to review the radiological features and treatment for the management of sacral chordoma.
    Neurosurgery Quarterly 01/2012; 22(1):12–15. DOI:10.1097/WNQ.0b013e31822776ea · 0.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Candida infections are the most frequent infections in neutropenic patients. Hepatosplenic candidiasis (HSC) is a part of disseminated Candida infection that occurs most commonly in patients with hematologic malignancies treated with chemotherapy and requires protracted antifungal therapy. During invasive mycosis with rapid resolution of immunosuppression, immune reconstitution inflammatory syndrome (IRIS) which mimics treatment failure, drug toxicity or breakthrough infections may occur. Manifestation period, histopathologic findings and favorable effect of steroids to its inflammatory symptoms strongly suggest that HSC belongs to the invasive fungal infection induced IRIS. We present a child with B cell-acute lymphoblastic leukemia who developed HSC and addition of corticosteroid therapy to antifungal treatment achieved rapid resolution of the clinical symptoms and laboratory findings.
    Mediterranean Journal of Hematology and Infectious Diseases 01/2012; 4(1):e2012018. DOI:10.4084/MJHID.2012.018
  • [Show abstract] [Hide abstract]
    ABSTRACT: Localization of malignant schwannoma in the head and neck region is rare. Malignant schwannoma is a highly aggressive, slowly growing, encapsulated tumor of nerve sheath origin. The most common presentation of this tumor is a subcutaneous progressively enlarging mass with or without neurologic symptoms. These tumors arise from neurofibromas with or without von Recklinghausen disease, and most of the remains develop from peripheral nerve trunks. We report a case with recurrent malignant schwannoma of the scalp that is an uncommon presentation and discuss the clinicopathologic properties of this tumor.
    The Journal of craniofacial surgery 05/2011; 22(3):1120-2. DOI:10.1097/SCS.0b013e3182108f69 · 0.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the frequency of MEFV mutations and their associations with the clinical and laboratory findings in children with Henoch-Schönlein purpura (HSP). One hundred and seven children with HSP were investigated for 12 common MEFV mutations. Forty-seven patients (43.9%) were found to have one of the MEFV mutations. Eight patients (7.5%) were homozygous for one mutation, 33 (30.8%) were heterozygous for one and six (5.6%) were compound heterozygous for two mutations. There were no age and sex differences between patients with or without mutations. Scrotal involvement was statistically more frequent in patients with mutations. Leucocyte counts, erythrocyte sedimentation rates, serum C-reactive protein (CRP) concentrations, number of patients with increased CRP levels and number of patients with increased immunoglobulin A concentrations were found to be higher in patients with MEFV mutations. p.M694V was the most frequent mutation and was found to have effects on clinical and laboratory findings in children with HSP. Fifteen patients were started on colchicine with the diagnosis of familial Mediterranean fever (FMF). MEFV mutations are more frequent in HSP than in the general population, and mutation carriers may have more severe clinical findings with higher inflammatory response, suggesting a dysregulation of the inflammatory response because of defective gene encoding the protein pyrine. Investigation of these mutations may be beneficial to follow-up the susceptible patients more closely leading to early diagnosis and treatment of FMF.
    Acta Paediatrica 05/2011; 100(5):745-9. DOI:10.1111/j.1651-2227.2011.02143.x · 1.84 Impact Factor

Publication Stats

14 Citations
10.54 Total Impact Points

Institutions

  • 2012–2014
    • Ankara Children's Hematology Oncology Training and Research Hospital
      Engüri, Ankara, Turkey
    • Ankara Atatürk Training and Research Hospital
      Engüri, Ankara, Turkey
  • 2011
    • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
      Engüri, Ankara, Turkey
    • Dr. Sami Ulus Children's Hospital
      Engüri, Ankara, Turkey